James W. Burns, Ph.D.

AIMBE College of Fellows Class of 2001
For pioneering work in the development of implantable devices based on the use of hydrogels for controlling the tissue biomaterials response.

Bayer, CRISPR Tap Sanofi Exec, Burns, to Run Gene Editing Venture

Via Xconomy | November 1, 2016

Bayer and CRISPR Therapeutics (NASDAQ: CRSP) have named James Burns the president and CEO of Cambridge, MA-based Casebia Therapeutics, a joint venture the two companies created to develop gene editing drugs for blood disorders, blindness, and heart disease. Burns has been at Sanofi/Genzyme for three decades, and most recently ran the company’s North American R&D hub. Bayer executive Axel Bouchon had been serving as Casebia’s interim CEO.